USANA Health Sciences, Inc. (NYSE:USNA) Insider Sells $106,657.32 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider David Mulham Mulham sold 3,234 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $32.98, for a total transaction of $106,657.32. Following the completion of the sale, the insider now owns 12,775 shares of the company’s stock, valued at approximately $421,319.50. This represents a 20.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

USANA Health Sciences Stock Performance

Shares of USANA Health Sciences stock opened at $33.07 on Wednesday. The stock has a market capitalization of $630.24 million, a P/E ratio of 11.68, a P/E/G ratio of 0.93 and a beta of 0.98. USANA Health Sciences, Inc. has a 52-week low of $27.71 and a 52-week high of $50.32. The stock’s 50-day simple moving average is $32.92 and its 200 day simple moving average is $36.13.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.49 by $0.15. The business had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. Equities research analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on USNA. DA Davidson cut their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Finally, Sidoti downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th.

Institutional Investors Weigh In On USANA Health Sciences

Several institutional investors have recently added to or reduced their stakes in the business. Martingale Asset Management L P lifted its holdings in USANA Health Sciences by 2.1% during the third quarter. Martingale Asset Management L P now owns 16,732 shares of the company’s stock valued at $634,000 after purchasing an additional 340 shares during the last quarter. KBC Group NV grew its holdings in USANA Health Sciences by 96.6% during the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares in the last quarter. R Squared Ltd purchased a new position in USANA Health Sciences during the 4th quarter valued at about $28,000. Safe Harbor Fiduciary LLC purchased a new position in USANA Health Sciences during the 3rd quarter valued at about $30,000. Finally, Exchange Traded Concepts LLC grew its holdings in USANA Health Sciences by 11.3% during the 4th quarter. Exchange Traded Concepts LLC now owns 8,578 shares of the company’s stock valued at $308,000 after buying an additional 869 shares in the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.